US · PLYX
Polaryx Therapeutics, Inc. Common Stock
- Sector
- Healthcare · Biotechnology
- Headquarters
- Paramus, NJ 07652
- Website
- polaryx.com
Price · as of 2024-12-31
$4.88
Market cap 143.62M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 |
AI valuation
Our deep-learning model estimates Polaryx Therapeutics, Inc. Common Stock's (PLYX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $4.88
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PLYX | Polaryx Therapeutics, Inc… | $4.88 | 143.62M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | -1013.73% | -582.60% | -829.85% | 0.00 | — | 17.30 | 15.99 | 1.06 | 70000.00% | — | 138728.00% | — | -8.90 | -344.44% | — | 0.00% | — | — | — | — | — |
| ANTX | AN2 Therapeutics, Inc. | $1.10 | 30.14M | — | — | — | — | -0.76 | 0.48 | — | -13.78 | — | 0.48 | 0.00% | — | — | -49.69% | -697.76% | -44.47% | 0.00 | — | 8.43 | 8.20 | -6.60 | -3723.00% | — | -756.00% | -126.06% | -4.81 | -630.01% | 0.00% | 0.00% | 14.60% | 0.82 | 0.90 | — | -1.80 |
| CBIO | Crescent Biopharma, Inc. | $12.09 | 333.16M | — | — | — | — | -7.78 | 5.75 | — | -6.38 | 0.00 | 5.75 | 0.00% | — | — | -143.95% | 59483.26% | -108.69% | 0.01 | -69.85 | 6.56 | 6.41 | 1.41 | 217244407.00% | — | 13290.00% | -6.21% | -1.98 | 28611.99% | 0.00% | 0.00% | 18.37% | -6.26 | -13.18 | — | 16.68 |
| FHTX | Foghorn Therapeutics Inc. | $5.68 | 332.74M | +360% | -68% | — | +572% | -2.86 | -5.45 | 10.98 | -0.43 | — | -5.45 | 100.00% | -454.31% | -383.24% | 141.17% | 39.62% | -30.40% | -0.82 | — | 3.73 | 3.64 | 0.19 | -3248.00% | -3383.00% | -1510.00% | -40.83% | -1.50 | 39.09% | 0.00% | 0.00% | 0.00% | -0.40 | -0.41 | 1.84 | -2.64 |
| HCWB | HCW Biologics Inc. | $0.54 | 1.16M | +6,101% | +980% | — | +51% | -18.86 | -83.66 | 220.66 | -20.79 | -188.64 | -83.66 | 37.38% | -1148.50% | -1169.70% | -897.37% | -320.11% | -102.21% | -2.02 | -25.45 | 0.19 | 0.18 | -0.33 | 1000.00% | -968.00% | -4954.00% | -2.56% | -0.48 | -157.33% | 0.00% | 0.00% | 0.00% | -19.52 | -39.71 | 224.17 | 0.44 |
| JBIO | Jade Biosciences, Inc. | $14.83 | 483.84M | — | — | — | — | -1.01 | 0.92 | — | 0.11 | — | 0.92 | 0.00% | — | — | -74.91% | 1059.60% | -67.03% | 0.01 | — | 20.93 | 20.54 | 0.48 | -1506.00% | — | 2508.00% | -101.04% | -18.60 | 1011.31% | 0.00% | 0.00% | 14.93% | 0.10 | 0.11 | — | 4.86 |
| KLRS | Kalaris Therapeutics Inc | $10.46 | 195.63M | — | — | — | — | -0.84 | 0.44 | — | 1.17 | — | 0.44 | 0.00% | — | — | -172.12% | 207.85% | -96.44% | 0.00 | — | 22.63 | 22.58 | 2.01 | -7213.00% | — | 37909.00% | -136.96% | -12.92 | 254.68% | 0.00% | 0.00% | 232.88% | 1.25 | 1.02 | — | -3.17 |
| KZR | Kezar Life Sciences, Inc. | $6.70 | 49.07M | +394% | — | — | — | -5.31 | 3.80 | — | -4.05 | — | 3.80 | 0.00% | — | — | -55.00% | -3029.25% | -45.77% | 0.14 | -56.88 | 6.76 | 6.53 | 0.32 | -1786.00% | -10000.00% | -1104.00% | -16.69% | -3.65 | -2482.15% | 0.00% | 0.00% | 2.03% | -3.63 | -4.43 | — | 4.31 |
| LYEL | Lyell Immunopharma, Inc. | $24.00 | 509.85M | -75% | -75% | — | +4,553% | -0.57 | 0.51 | 3184.91 | 0.58 | -1.41 | 0.51 | 100.00% | -588122.95% | -562285.25% | -66.10% | -295.08% | -55.28% | 0.15 | — | 7.06 | 6.89 | 0.23 | 4014.00% | -5308.00% | -212.00% | -83.83% | -3.02 | -133.95% | 0.00% | 0.00% | 0.00% | 0.33 | 0.72 | -1922.61 | -4.37 |
| NXTC | NextCure, Inc. | $12.72 | 34.09M | — | — | — | — | -0.38 | 0.32 | — | 0.77 | — | 0.32 | 0.00% | — | — | -61.87% | -769.60% | -53.28% | 0.09 | — | 7.50 | 7.20 | 0.40 | -1168.00% | — | -2326.00% | -196.82% | -4.26 | -531.71% | 0.00% | 0.00% | 72.95% | 0.70 | 1.01 | — | -7.28 |
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., operates as a biotech company that develops small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders. Its pipeline includes PLX-100, a combination of PLX-200 and a supplement for late infantile neuronal ceroid lipofuscinosis (LINCL) and other forms of NCL; PLX-200, a repurposed drug that is used to treat other diseases in adults and children; and PLX-300, a drug isolated from an edible plant that activates PPARa, which enhances production of transcription factor EB. The company was founded in 2014 and is based in Paramus, New Jersey.
- CEO
- Alex Yang
- Employees
- 11
- Beta
- 0.00
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $4.88) − 1 = — (DCF, example).